2025年1月22日 · Abelacimab is a fully human monoclonal antibody that binds to the inactive form of factor XI and blocks its activation. The safety of abelacimab as compared with a direct oral anticoagulant...

Abelacimab (MAA868), is a fully human monoclonal antibody for the treatment of thrombosis, [1] under development by Anthos Therapeutics. It is anti-factor XI antibody.

2 天之前 · Abelacimab significantly reduced the risk of major and clinically relevant non-major bleeding compared with rivaroxaban across all age groups, with a greater absolute risk reduction (ARR) in older ...

2023年11月12日 · Abelacimab is an injectable, monoclonal antibody, categorized as a factor XI inhibitor, that has the potential to prevent the clots that cause strokes and heart attacks while preserving the body’s natural ability to repair blood vessels during an injury.

2021年7月19日 · Abelacimab (MAA868) is a fully human monoclonal antibody that binds to the catalytic domain of factor XI and locks it in the zymogen (inactive precursor) conformation, thereby preventing its ...

2023年11月17日 · Abelacimab is an injectable, experimental, anti-clotting medication that is categorized as a factor XI inhibitor. It has the potential to prevent the clots responsible for strokes and heart attacks while preserving the body's natural ability to repair blood vessels after an injury.

3 天之前 · In contrast, bleeding rates with abelacimab remained remarkably low—typically in the range of 2% to 4%. Given that more than half of atrial fibrillation patients are at high risk for bleeding, the fact that abelacimab offers a 60% to 70% reduction in bleeding is significant.

2 天之前 · The AZALEA-TIMI 71 clinical trial that compares abelacimab to Xarelto (rivaroxaban) has brought the solely generic-named abelacimab into the spotlight as a promising alternative to rivaroxaban for anticoagulation therapy, a treatment that prevents blood clots from forming or growing.. However, questions remain about how it compares to other direct oral anticoagulants …

2025年1月22日 · Findings suggest abelacimab could transform AFib management by reducing bleeding complications and enhancing anticoagulation therapy. Clinically significant reductions in bleeding underscore...

2025年2月11日 · Abelacimab showed a 60-70% reduction in bleeding events compared to rivaroxaban, leading to early trial termination.